Total Payments
$147,953
2024 Payments
$13,368
Companies
10
Transactions
119
Medicare Patients
435
Medicare Billing
$67,028
Payment Breakdown by Category
Consulting$102,396 (69.2%)
Research$19,175 (13.0%)
Other$13,164 (8.9%)
Travel$10,303 (7.0%)
Food & Beverage$2,827 (1.9%)
Gifts$55.00 (0.0%)
Education$32.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $102,396 | 52 | 69.2% |
| Unspecified | $19,175 | 7 | 13.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,074 | 7 | 8.8% |
| Travel and Lodging | $10,303 | 26 | 7.0% |
| Food and Beverage | $2,827 | 22 | 1.9% |
| Entertainment | $90.00 | 1 | 0.1% |
| Gift | $55.00 | 1 | 0.0% |
| Education | $32.92 | 3 | 0.0% |
Payments by Type
General
$128,778
112 transactions
Research
$19,175
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $46,150 | 13 | $0 (2019) |
| Celgene Corporation | $27,750 | 15 | $0 (2023) |
| National Marrow Donor Program | $18,839 | 51 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $15,826 | 8 | $0 (2024) |
| CSL Behring | $15,155 | 7 | $0 (2023) |
| Merck Sharp & Dohme LLC | $12,522 | 20 | $0 (2022) |
| Cidara Therapeutics, Inc. | $6,300 | 2 | $0 (2023) |
| Gilead Sciences Inc | $3,000 | 1 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $2,400 | 1 | $0 (2021) |
| Kite Pharma, Inc. | $10.58 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,368 | 19 | National Marrow Donor Program ($8,928) |
| 2023 | $16,461 | 30 | National Marrow Donor Program ($7,321) |
| 2022 | $15,510 | 20 | CSL Behring ($5,859) |
| 2021 | $21,578 | 15 | CSL Behring ($7,656) |
| 2020 | $18,325 | 11 | Celgene Corporation ($9,600) |
| 2019 | $26,400 | 11 | Shire North American Group Inc ($22,100) |
| 2018 | $31,811 | 11 | Shire North American Group Inc ($24,050) |
| 2017 | $4,500 | 2 | Gilead Sciences Inc ($3,000) |
All Payment Transactions
119 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/15/2024 | National Marrow Donor Program | — | Gift | In-kind items and services | $55.00 | General |
| 11/08/2024 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $124.10 | General |
| 11/08/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $20.22 | General |
| 09/20/2024 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $410.00 | General |
| 09/20/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $100.00 | General |
| 09/19/2024 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $465.51 | General |
| 07/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 07/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 07/03/2024 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $89.98 | General |
| 06/07/2024 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $410.00 | General |
| 06/07/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $158.00 | General |
| 06/06/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $209.00 | General |
| 06/05/2024 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $310.47 | General |
| 02/16/2024 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $109.53 | General |
| 02/16/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $28.33 | General |
| 01/19/2024 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $867.00 | General |
| 01/19/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $481.00 | General |
| 01/18/2024 | National Marrow Donor Program | — | Entertainment | In-kind items and services | $90.00 | General |
| 01/05/2024 | National Marrow Donor Program | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,000.00 | General |
| 12/15/2023 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $720.32 | General |
| 12/06/2023 | National Marrow Donor Program | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $575.00 | General |
| 12/04/2023 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 12/01/2023 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $42.00 | General |
| 12/01/2023 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $20.35 | General |
| 11/22/2023 | Cidara Therapeutics, Inc. | REZZAYO (Drug) | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SHP620 COMPARED TO VALGANCICLOVIR FOR THE TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN STEM CELL TRANSPLANT RECIPIENTS | Takeda Pharmaceuticals U.S.A., Inc. | $9,425 | 4 |
| A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SHP620 COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF CYTOMEGALOVIRUS CMV INFECTIONS THAT ARE RESISTANT OR REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, FOSCARNET, OR CIDOFOVIR IN TRANSPLANT RECIPIENTS | Shire North American Group Inc | $6,500 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SHP620 COMPARED TO VALGANCICLOVIR FOR THE TREATMENT OF CYTOMEGALOVIRUS CMV INFECTION IN STEM CELL TRANSPLANT RECIPIENTS | Shire North American Group Inc | $3,250 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 84 | 181 | $63,412 | $12,831 |
| 2022 | 3 | 100 | 203 | $77,858 | $16,190 |
| 2021 | 4 | 138 | 349 | $120,553 | $27,192 |
| 2020 | 2 | 113 | 206 | $51,182 | $10,815 |
Total Patients
435
Total Services
939
Medicare Billing
$67,028
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 50 | 76 | $26,752 | $4,822 | 18.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 68 | $17,272 | $4,151 | 24.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 37 | $19,388 | $3,858 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 69 | 137 | $48,650 | $9,733 | 20.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 20 | 32 | $16,798 | $3,716 | 22.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 34 | $12,410 | $2,741 | 22.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 85 | 219 | $70,779 | $15,953 | 22.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 92 | $33,970 | $7,630 | 22.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 16 | $11,478 | $2,533 | 22.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 18 | 22 | $4,326 | $1,077 | 24.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 77 | 149 | $40,989 | $8,663 | 21.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 36 | 57 | $10,193 | $2,151 | 21.1% |
About Dr. John Wingard, MD
Dr. John Wingard, MD is a Medical Oncology healthcare provider based in Gainesville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700818150.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Wingard, MD has received a total of $147,953 in payments from pharmaceutical and medical device companies, with $13,368 received in 2024. These payments were reported across 119 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($102,396).
As a Medicare-enrolled provider, Wingard has provided services to 435 Medicare beneficiaries, totaling 939 services with total Medicare billing of $67,028. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Gainesville, FL
- Active Since 07/07/2006
- Last Updated 03/05/2008
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1700818150
Products in Payments
- PREVYMIS (Drug) $10,272
- Hizentra (Biological) $8,956
- REZZAYO (Drug) $6,300
- Privigen (Biological) $6,200
- ABECMA (Biological) $3,000
- Yescarta (Drug) $10.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Gainesville
Dr. George Kim, M.d, M.D
Medical Oncology — Payments: $1.0M
Medical Oncology $1.0M
Dr. Coy Heldermon, Md, MD
Medical Oncology — Payments: $47,064
Medical Oncology $47,064
Christopher Cogle, Md, MD
Medical Oncology — Payments: $33,817
Medical Oncology $33,817
Andrew Johnson, M.d, M.D
Medical Oncology — Payments: $21,882
Medical Oncology $21,882
Richard Locicero, M.d, M.D
Medical Oncology — Payments: $12,834
Medical Oncology $12,834
Devi Sampat, Md, MD
Medical Oncology — Payments: $10,292
Medical Oncology $10,292